Bevacizumab injection | China Drugs List
Public reference information, not medical advice, a prescription or an offer to supply a medicine. Confirm current approval, availability and suitability with licensed professionals.
Others
- Brand
- Avastin
- Company
- Genentech, Inc. (US product); Roche Registration GmbH (EU authorization holder)
- Medicine type
- Biologic
- Therapeutic area
- Oncology
- Indications recorded in the public source
- United States source summary: Selected uses include metastatic colorectal cancer with fluorouracil-based chemotherapy; first-line unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer with carboplatin/paclitaxel; recurrent adult glioblastoma; metastatic renal cancer with interferon alfa; and specified cervical and ovarian/fallopian-tube/peritoneal cancers with chemotherapy. With atezolizumab for unresectable or metastatic hepatocellular carcinoma without prior systemic therapy. Regimen, prior-treatment and disease-stage restrictions differ by indication; see the linked label.
- Indication source and scope
- US prescribing information, revised September 2022; accessed 2 November 2026.. Selected overseas indications; does not establish the Chinese approved scope.
- Prescribing-information limitations
- Overseas official prescribing information linked; a complete current Chinese label has not been verified.
- China availability status
- Chinese approval, current approved indications and continuous market availability have not been independently verified in this English-source review.
- Overseas status
- See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
- Insurance classification
- Not yet verified
- Insurance edition
- Chinese national insurance review pending
- Insurance verification notes
- No reimbursement determination was made for this addition; missing information is not proof of exclusion.
Sources
- https://www.gene.com/download/pdf/avastin_prescribing.pdf
- Avastin — official United States product information
Official prescribing information · US prescribing information, revised September 2022; accessed 2 November 2026.
Full official PDF opened; medicine identity and relevant indication text checked. This overseas source does not establish the Chinese approved scope.
- Avastin — EMA assessment and product overview
Regulatory product overview · Accessed 2 November 2026
English regulatory reference; authorization holder is identified for the EU product, not a Chinese generic or biosimilar.
- Texas DSHS — 2026 annual WAC report
Supplied report reference · Report dated 25 October 2026
Original report citation retained for traceability. This citation alone does not verify Chinese approval, brand identity, equivalent formulations or like-for-like prices. WAC unit and pack conversions require separate confirmation.
- FDA NDC directory — packaging reference
Supplied report reference · Report dated 25 October 2026
Original report citation retained for traceability. This citation alone does not verify Chinese approval, brand identity, equivalent formulations or like-for-like prices. WAC unit and pack conversions require separate confirmation.
Evidence reviewed:
Open the interactive record, public price references and discussions